|
|
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows:
- Collaboration revenue (79.8%);
- Grant revenue (20.2%).
At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and three in phase I. |
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | Transformative Medicines | 135.07 | 100% | 60.21 | 100% | -55.42% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | United States | 135.07 | 100% | 60.21 | 100% | -55.42% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
399,769,582 |
356,195,060 |
89.1% |
0 |
0.0% |
89.1% |
|
|
|
| Name | Equities | % | | Flagship Pioneering | 24,333,423 |
6.15% | | Baillie Gifford & Co. | 24,312,271 |
6.14% | | Stéphane Bancel | 23,183,780 |
5.86% | | The Vanguard Group, Inc. | 22,687,508 |
5.73% | | Robert Langer | 11,509,357 |
2.91% | | Fidelity Management & Research Co. LLC | 7,940,013 |
2.01% | | BlackRock Fund Advisors | 7,391,851 |
1.87% | | SSgA Funds Management, Inc. | 6,024,687 |
1.52% | | Thélème Partners LLP | 5,343,698 |
1.35% | | Geode Capital Management LLC | 3,571,240 |
0.90% |
|
|
|
|
- - Nasdaq Global Select Market - Nasdaq 100 / |
|
|
|
|
| - Bloomberg Code : |
|
| - Reuters Code : |
MRNA.O |
| - Datastream Code : |
|
|
| Company contact information |
|
Moderna, Inc. 200 Square Technology MA 02139 Cambridge, Massachusetts Phone : +1 617 714 6500 Fax : +1 617 583 1998 web site : https://www.modernatx.com |
|
|
|
Moderna : Biden says 'big mistake' for states to lift mask mandates given virus toll |
Sector Other Biotechnology & Medical Research
Connections : Moderna, Inc. |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
